1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors

Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors

  • February 2014
  • -
  • La Merie Publishing
  • -
  • 98 pages

TNF Antibodies –Biosimilars and Biosuperiors
The present Competitive Intelligence Report about TNF Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The therapeutic drug class of TNF antibodies presently consists of five different approved and marketed products which all together achieved worldwide sales of US$ 30.5 bln in 2013. Among the approved indications for use of TNF antibodies in general are rheumatoid arthritis, idiopathic juvenile arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, psoriasis, ulcerative colitis and Crohn’s disease. However, not all TNF antibodies are the same and their efficacy had to be demonstrated for each indication.
The highly attractive market and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. For all of the five marketed TNF antibodies are biosimilar molecules in the R&D pipeline, but with clear priority on the first generation TNF antibody constructs.
The report includes a compilation of currently active projects in development of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: TNF Antibodies -Biosimilars and Biosuperiors
TNF Antibodies -Biosimilars and Biosuperiors
Table of Contents
1. TNF Antibodies -Biosimilars and Biosuperiors

Marketed TNF Antibodies

-           Humira Sales and Pipeline

-           Remicade Sales and Pipeline

-           Enbrel Sales and Pipeline

-           Simponi Sales and Pipeline

-           Cimzia Sales and Pipeline

Biosuperior / Biobetter TNF Antibodies

Biosimilar TNF Antibodies

-           Humira Biosimilar Antibody Pipeline

-           Remicade Biosimilar Antibody Pipeline

-           Enbrel Biosimilar Antibody Pipeline

-           Simponi Biosimilar Antibody Pipeline

-           Cimzia Biosimilar Antibody Pipeline

2.  Corporate TNF Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...

Global Biosimilar Drug Market Research Report 2016

Global Biosimilar Drug Market Research Report 2016

  • $ 2850
  • Industry report
  • November 2016
  • by 9Dimen Research

2016 Global Biosimilar Drug Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilar Drug industry, focusing on the main regions ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.